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UPRERp29 is an endoplasmic reticulum (ER) luminal protein with a putative secretion factor/escort chaperone
function. Accumulated evidence has implicated ERp29 in the thyroglobulin secretion, polyoma virus transport
and recently in carcinogenesis. ERp29 levels were elevated in the tumors of various origins and under the
conditions of genotoxic stress, such as ionizing radiation. Here we report the induction of ERp29 during the
treatment of cells with doxorubicin, a commonly used antineoplastic agent. Experiments in the p53−/− cells
and p53 knockout mouse revealed that doxorubicin effect on ERp29 is p53 dependent. The increase of ERp29
level appears to activate a negative feedback loop where the elevated amounts of ERp29 augment cell viability
as shown by a clonogenic cell survival assay. To elucidate the mechanisms behind the doxorubicin effects we
have studied the impact of ERp29 on the interaction with the ER stress-activated eukaryotic translation
initiation factor 2-alpha kinase 3 (PERK) that was shown to facilitate tumor cells' resistance to drug toxicity.
Co-immunoprecipitation demonstrated physical interaction of ERp29 with PERK and moreover, over-
expression of ERp29 enhanced endogenous levels of PERK. Our results identify ERp29 as a novel regulator of
PERK and provide evidence for the role of ER resident factors in the regulation of chemotherapeutic efﬁcacy.
These ﬁndings show that PERK may represent a nodal point between ER stress and chemotherapeutic
response.l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
ERp29 is a relatively small (29 kDa) protein localized in the luminal
compartment of the ER. Despite the structural resemblance to the protein
disulﬁde isomerases (PDI) as manifested by the thioredoxin-like N-
terminal domain, ERp29 has no characteristic disulﬁde isomerase or
chaperone activity [1]. It is ubiquitously expressed with the highest
expression in the secretory cells [2]. Such expression proﬁle and also
involvement in the secretionof thyroglobulin andother secretoryproteins
suggest a possible secretion factor/escort chaperone function [3]. Recent
evidence also implicated ERp29 in pathological processes, such as
polyoma virus infection and tumorigenesis, roles that are most likely
dependent on its endogenous secretion function [4–6].
The ER is often challenged by the rapid accumulation of misfolded
proteins (ER stress) caused by a variety of pathological or physiological
impacts. The ER protein folding and secretory capacity is regulated by
the adaptive cellular mechanism termed unfolded protein response
(UPR). UPR is triggered upon activation of the three ER stress sensor
molecules, transcription factor ATF6 and two receptor kinases, IRE1 and
eukaryotic translation initiation factor 2-alpha kinase 3 (PERK) [7]. The
combined effect of their activation is a temporary inhibition of the
protein translation (PERK), induction of molecular chaperones andother prosurvival factors implicated in the protein folding, secretion and
even protein degradation (ATF6 and IRE1) [7].
ERp29was proposed to be involved in the UPR as a factor facilitating
transport of newly synthesized secretory proteins. The increased
expression of ERp29 was demonstrated in the certain cell types both
under the pharmacologically induced UPR and under the physiological
conditions (lactation, differentiation of thyroid cells) [6,8]. In addition to
UPR, ERp29 expression has been recently shown to be enhanced by yet
another disturbance of cell homeostasis, namely genotoxic stress. As
shown by Zhang et al. [9] ERp29 levels were elevated in the cells
exposed to the ionizing radiation, a known DNA damaging factor. Cells
have evolved an adaptive response system to such genotoxic impacts
that includes cell cycle arrest, activation of the DNA repair or, in the case
of irreparable damage, apoptosis [10]. These mechanisms are also
activated upon administration of the widely used antineoplastic agent,
doxorubicin (DOX) that acts via the intercalation of DNA and
subsequent activation of the tumor suppressor p53 [10]. Interestingly,
although UPR is mostly a prosurvival adaptive response, the excessive
ER stress may also activate the apoptotic pathway, similar to the
genotoxic stress response, and is largely dependent on PERK [11]. PERK
activation results in the inhibition of protein translation due to the
phosphorylation of a general translation factor eIF2α but also in the
initiation of a pro-apoptotic program that includes activation of CHOP/
GADD153 transcription factor and Bim [11,12]. In addition, induction of
PERKpathwaymay result in the cell cycle arrest caused by the inhibition
of synthesis of cell cycle regulators, such as cyclin D1 [13].
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protein whose expression is increased under UPR, and which was
proposed to play a protective role in genotoxic stress [9], might be
involved in a common for these two pathways mechanism(s). Indeed,
here we demonstrate that, ERp29 is upregulated in response to the
administration of the anticancer agent doxorubicin in a p53-dependent
manner, interacts physically with PERK and confers resistance to DOX.
2. Materials and methods
2.1. Cell culture, transfection and treatment with DOX
Α549 human lung epithelial adenocarcinoma cells and PC-3 prostate
adenocarcinoma cells were maintained in DMEM containing 10% FBS
and antibiotics/antimycotics. MEFs were isolated at E11.5 from female
p53 heterozygousmice that have beenmatedwith heterozygousmales,
by using standard procedures and were subsequently genotyped to
assess the p53 zygosity status as previously described [14].
For transient transfection experiments, the cells were seeded 24 h
prior to transfection and transfected by using the Lipofectamine 2000
reagent (Invitrogen) according to the manufacturer's instructions. Cells
were harvested and analyzed 48 h later, if not otherwise stated. For
immunoblot analysis, binding and survival assays, cells were transiently
transfected with empty pcDNA 3.1 plasmids (mock) or plasmids
encoding for ERp29 (pcDNA3.1-ERp29) [15], pcDNA3.1-ERp29/C157Fig. 1. p53-dependent induction of ERp29 by DOX. DOX induces ERp29 protein levels as detec
cells but not in p53-null cells, such as PC3 prostate adenocarcinoma cells and p53-null ME
shown adjacent to each immunoblot (A, B, and C). C. ERp29 is shown in green and nuclei we
exposure.(a mutant of ERp29 that was suggested to operate as a dominant-
negative form of the protein) [15], PERK (pcDNA1-PERK), mutant PERK
(pcDNA1-PERK-K618A dominant negative mutant, kindly provided by
Dr Antonis Koromilas) [16] or siRNA for ERp29 (sc-60599, Santa Cruz).
siRNA transfection was performed using Lipofectamin 2000 reagent
(Invitrogen). For p-eIF2α detection A549 cells were transiently
transfected with pcDNA3.1-ERp29 and pcDNA3.1-ERp29/D42A
(a mutant of ERp29 that fails to dimerize) [17], harvested and analyzed
4 or 8 h later.
For immunoblot analysis, RT-PCR analysis, binding and survival
assays, cells were treated with 0.1–0.2 μM DOX (Sigma) or vehicle
(DMSO) for 24 h. For UPR induction control, cells were treated with
5 μg/ml Tunicamycin (Sigma) for 4 or 8 h.
2.2. RT-PCR analysis
RNA was isolated using Trizol Reagent (Invitrogen), according to
the manufacturer's instructions. cDNA was obtained after a two-step
reaction using AMV-RT (Promega). Detailed PCR conditions have been
described previously [18].
2.3. Western blot analysis
For immunoblot analysis cells were solubilized with ice-cold RIPA
buffer (Thermo Scientiﬁc) supplemented with protease inhibitorted by immunoblot analysis in the p53 positive cells, such asMEFs and A549 lung cancer
Fs. The densitometric quantiﬁcation of these results (normalized to the actin levels) is
re identiﬁed by DAPI (blue). D. Induction of p53 expression in A549 cells following DOX
Fig. 2. RT-PCR analysis of ERp29 and BiP mRNA expression after DOX treatment in A549
cells. cDNA from A549 cells was ampliﬁed using gene speciﬁc primer pairs in 25 cycles.
PCR fragments were resolved on EtBr agarose gel (upper panel). Lower panel represents
results of the densitometric analysis of ERp29 and BiP PCR fragments after
normalization to the actin levels.
Fig. 3. Cell density mediated regulation of ERp29 expression is independent of p53.
Western blot detection of ERp29 expression in the MEFs from wild type or p53-null
mice cultured under conditions of low density (lower than 40%) and high density
(above 95%).
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was determined by using Bradford assay (Biorad). Equal amounts of
total proteinwere resolved by SDS-PAGE and immunoblottedwith anti-
ERp29 [3], anti-BiP (NeoMarkers), anti-p21 (sc-6246; Santa Cruz), anti-
PERK (sc-13073; Santa Cruz), anti-p53 (sc-71817; Santa Cruz), anti-p-
eIF2α (#33985; Cell Signaling), anti-eIF2α (sc-11386; Santa Cruz) and
anti-actin (Sigma). Relative protein amounts were evaluated by a
densitometric analysis using ScienceLab software (Fujiﬁlm). Levels of
expression are shown in arbitrary units and normalized to the
corresponding actin levels, unless otherwise stated. All experiments
have been performed at least 3 times and representative results and the
corresponding quantiﬁcation data of one experiment are shown.
2.4. Immunoﬂuorescent microscopy
A549 cells were treated with 0.2 μM DOX or vehicle for 24 h, ﬁxed
and stained as described previously [3]. Images were analyzed using
LSM T-PMT confocal microscope (Zeiss) and 60X oil immersion
objective.
2.5. Immunohistochemistry
Livers were obtained from 8 weeks old wild type or p53-deﬁcient
mice that were treated with a single i.p. injection of DOX (4 mg/kg) or
vehicle (DMSO) for 24 h. Liver sections (4-μm-thick) from parafﬁn-
embedded blocks were collected onto poly-L-lysine-coated slides and
stained with anti-ERp29 [3] by using the SuperPicture HRP Polymer
Conjugate Broad Spectrum (DAB) kit (Zymed Laboratories Inc.),
according to the manufacturer's instructions and counterstained with
hematoxylin.
2.6. Immunoprecipitation
A549 cells or MEFs after treatment with DOX or transfection as
described in the Results' section were lysed in a buffer containing
50 mM Τris HCl, 150 mMNaCl, 1% Triton X-100, 5 mMEDTA, and 1 mM
DTT), protease inhibitor cocktail (ThermoScientiﬁc), spanneddownand
the supernatant was immunoprecipitatated with anti-PERK (sc-13073;Santa Cruz) for overnight. ProteinA/G beads (sc-2003; Santa Cruz)were
used to isolate the antibody–protein complexes, which were washed
twice with lysis buffer, resuspended in 40 μl of SDS buffer and
immunoblotted with anti-ERp29 [3], anti-BiP (NeoMarkers), anti-
PERK (sc-13073; Santa Cruz) and anti-actin (Sigma).
2.7. Clonogenic cell survival assay
For clonogenic survival assays cells were transiently transfectedwith
pcDNA3.1-ERp29andpcDNA1-PERK/K618A. Co-transfectionof pcDNA1-
PERK/K618A and pcDNA3.1-ERp29 was performed at 3:1 molar ratio.
Since no antibiotic resistance is conferred by the pcDNA1 plasmid, co-
tranfection with empty vector pcDNA3.1 has been performed in a
manner that all experimental sets have received equimolar amount of
pcDNA3.1 or pcDNA3.1-ERp29. In order to diminish the consequences of
non-speciﬁc DNA-mediated toxicity, total DNA for each transfectionwas
adjusted to the ﬁnal amount of 2 μg by using the plasmid pUC19. 24 h
post transfection, cells were treatedwith 0.2 μMDOX or vehicle (DMSO)
for 24 h, selected in the presence of 1 mg/ml of G418 for 10 days and
counted using the trypan blue exclusion assay.
3. Results
3.1. p53-dependent induction of ERp29 by doxorubicin
In view of a recent report that identiﬁed ERp29 as a radiation-
induced gene [9], we have asked if genotoxic stress, such as that elicited
by the chemotherapeutic agent DOX [10] may also stimulate ERp29
expression. Indeed, exposure of the human lung cancer cells A549 and
wild type MEFs to DOX, resulted in the enhancement of ERp29 both on
protein (Fig. 1) and mRNA (Fig. 2) levels. Semi-quantitative RT-PCR
analysis in A549 cells suggested that the mRNA increase was not as
pronounced as the one observed at the protein level (~0.5-fold and 0.2-
fold higher levels than those of the controls as opposed to ~2-fold and 5-
fold induction for 0.1 μΜ and 0.2 μΜDOX respectively). Thismay reﬂect
the existence of the additional post-transcriptional mechanisms of
ERp29 regulation (Fig. 2). In order to discriminate between genotoxic
stress and UPR we have tested same cells for the expression of the
abundant ER chaperone BiP, the primary indicator of UPR [19]. BiP levels
remained essentially unaffected (Fig. 1A,B), despite some induction in
the MEFs exposed to 0.1 μΜ doxorubicin (Fig. 1B). As DOX-mediated
DNA damage leads to the activation of themajor tumor suppressor p53
[10], we have monitored the p53 activity during DOX treatment by
Fig. 4. DOX increases ERp29 expression in the livers of wild type but not the p53 null mice. Liver sections were stained with anti-ERp29 and counterstained with hematoxylin. i,ii,iii,
ERp29 immunoreactivity in the livers of 8 weeks old wild type or p53-deﬁcient (iv,v,vi) mice [22]. iii and vi are low resolution microphotographs of sections shown in ii and v. DOX
(4 mg/kg) was administered 24 h prior to the sacriﬁce of mice.
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amounts of p21 (Fig. 1A,B) and p53 (Fig. 1D) conﬁrmed that the cells
underwent a canonical DOX-dependent genotoxic stress response with
the activation of p53 and its downstream targets. Nextwe have decidedFig. 5.Physical interaction of PERKandERp29. A.ERp29 co-immunoprecipitateswith PERK inA5
increasing amounts of ERp29-expressing plasmids. C. Immunoprecipitation of A549 cells andM
Amounts of plasmid are shown above the immunoblots. Actin levels were used as a loading con
image; IP, immunoprecipitate; S, supernatant.to test whether the DOX-mediated ERp29 expression is dependent on
p53. Indeed, in the p53 deﬁcient human PC3 prostate cancer cells [21]
and in the MEFs isolated from p53-null mice [22], DOX failed to induce
the expressionof ERp29 (Fig. 1A,B). It is of note that thepatternsofDOX-49 cells B. Immunoblot analysis of A549 cells for BiP and ERp29 following transfectionwith
EFs by anti-PERK antibody following the exposure of cells to DOX at 0.1 and 0.2 μMfor 24 h.
trol. Densitometric quantiﬁcation of IP bands is shown at the bottom of each immunoblot
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p53 is apparently not the sole regulator of ERp29 following the DOX
exposure.
In addition, these in vitro ﬁndings were supported by the increased
ERp29 immunoreactivity that was detected in the livers of wild type
but not of p53-deﬁcient mice after the administration of DOX (Fig. 4).
ERp29 immunoreactivity was observed in clusters of hepatocytes, an
observation that probably reﬂects the bioavailability of DOX in the
livers of the experimental animals. Thus, an intact p53 response is
essential for the upregulation of ERp29 following the genotoxic stress
as induced by DOX.
We have shown earlier that ERp29 expression positively correlates
with the cell culture density [6]. It was therefore interesting to test
whether this effect might also be dependent on p53. However,
manipulation of p53 genetic status in MEFs had no effect on ERp29
expression (Fig. 3), reﬂecting apparently a different role of p53 for the
regulation of ERp29 by cell culture density and DOX.
3.2. ERp29 interacts with PERK
As mentioned earlier, it is conceivable that both UPR and genotoxic
stress responsemay share, at least in part, some regulatorymechanisms.
A likely candidate may be the critical UPR sensor, PERK. We have
explored this hypothesis by testing initially if ERp29 interacts physically
with PERK. Indeed, immunoprecipitation (IP) studies in A549 cells that
are able to execute an canonical UPR and also express high endogenous
PERK levels [23], conﬁrmed that ERp29 binds to PERK (Fig. 5A), in line
with a previous suggestion by Park et al. [24]. Interestingly, the amounts
of ERp29 bound to PERK were only marginally increased upon the
transfection with the increasing amounts of ERp29 encoding plasmids ,
suggesting that at least in resting conditions nearly all PERK molecules
are occupied by ERp29 (Fig. 5A). Since in quiescent cells PERK (aswell as
the other UPR sensors) is usually silenced by the physical interactionFig. 6. ERp29 affects PERK levels. A. Immunoblot analysis of PERK and ERp29 following the
ERp29. B. Immunoblot analysis of ERp29 following the transfection of A549 cells with pcDN
indicated above the immunoblots. C. Phosphorylation of eIF2α following the transfection of
for 4 or 8 h. Actin or total eIF2α levels were used as a loading control. Tun, tunicamycin.with BiP [19] we have tested whether ERp29 may interfere with this
mechanism. Overexpression of ERp29 demonstrated that this is not the
case, ruling out the possibility that ERp29may interfere directlywith the
binding of BiP to PERK (Fig. 5A,B).When, however, cellswere exposed to
DOX that stimulates the ERp29 expression (Fig. 1A,B, and C), the amount
of BiP thatwas bound to PERKwas higher in both A549 cells and inMEFs
(Fig. 5C). Since BiP levels were not affected by ERp29 (Fig. 5B) we
hypothesized that ERp29might somehow affect the total levels of PERK.
Indeed, as shown on Fig. 6A, ERp29 overexpression enhanced the total
PERK levels, while suppression of ERp29 expression by siRNA or by a
dominant negative formof theprotein resulted in the reduction of PERK.
In line with these data DOX treatment elevated the total PERK levels as
evidenced by the increased amount of immunoprecipitated PERK
following the exposure of MEFs, and to a lesser extent of A549 cells, to
DOX (Fig. 5C). The existence of the reverse regulatory loop, namely
modulation of ERp29 expression by PERK, is a less likely scenario since
the overexpression of neither wild type nor mutant PERK had any effect
on the ERp29 levels in A549 cells (Fig. 6B).
The ERp29-driven increase of PERK levels was detected on the
protein level (Fig. 6A),while quantitative PCRdata failed to demonstrate
a similar trend implying the involvement of other, most probably post
transcriptional mechanisms (data not shown).
In order to test whether ERp29 may modulate not only the levels of
PERK but also its main activity, i.e. the phosphorylation of eIF2α, we have
immunoblotted A549 cells for the phosphorylated form of eIF2α, 4 h and
8 h after the transfection with wild type and mutant ERp29 plasmids.
Indeed, 8 h after the transfection the phosphorylation of eIF2α was
positively affected by thewild type ERp29whereas the transfection of the
mutant ERp29 resulted in the decrease of p-eIF2α (Fig. 6C). Given the
relative weakness of the wild type ERp29 effect, this observation can be
interpreted as that ERp29 is needed but not sufﬁcient for PERK activation.
While BiP expressionwasnot affected byDOX(Fig. 1A,B) it increased
the binding of BiP to PERK (Fig. 5C) in both A549 cells andMEFs. It couldtransfection of A549 cells with pcDNA3.1-ERp29, pcDNA3.1-ERp29/C157 or siRNA for
A1(mock), pcDNA1-PERK and pcDNA1-PERK/K618. Amounts of plasmid or siRNA are
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Fig. 7. ERp29 reduces the sensitivity of A549 cells to DOX in a PERK dependent manner.
Clonogenic cell survival assay of A549 cells following the exposure of cells to DOX. Cell
viability assays were performed in triplicates and average values +/− standard error of
mean are shown on the graph. ERp29 overexpression increased the number of cells by
about 20% vs. controls while mPERK restored sensitivity of the cells against DOX. P values
(student's t-test) are shown.
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since plasmid-mediated overexpression of ERp29 was insufﬁcient to
increase total BiP levels, as well as the amount of BiP bound to PERK
(Fig. 5A,B) we suggest that the regulation of BiP binding to PERK during
DOX treatment is more complex and does not simply reﬂect the ERp29-
dependent availability of PERK.
3.3. ERp29 regulates cell viability after DOX treatment
In an attempt to explore the physiological relevance of ERp29
stimulation by DOX we have examined the consequences of ERp29
overexpression on the viability of cells treatedwithDOX. ERp29 reduced
the sensitivity of A549 cells to DOX as shown by clonogenic cell survival
assay (Fig. 7) suggesting that ERp29 confers resistance to DOX.
Furthermore, this effect was abolished by the overexpression of a
mutant form of PERK, incapable of phosphorylating eIF2α [16] (Fig. 7)
suggesting that the ERp29-dependent regulation of cell viability is
mediated, at least in part, by PERK. These results are also consistent with
the recently reported anti-apoptotic activity of ERp29 in cancer cells [25].
4. Discussion
The involvement of ER stress signaling in the cell survival during
chemotherapy remains poorly explored. Present study suggests that the
genotoxic stress response and UPR may have a common nodal point,
namely one of the major sensors of UPR, PERK. Moreover, there are
indications that PERK might be involved in the regulation of the
therapeutic efﬁcacy of DOX via the interactionwith the putative secretion
factor/escort chaperoneERp29, theassumption that is currently examined
in more details in our laboratory.
Although ERp29 does not appear to affect PERK- and eventually UPR-
activation per se, by increasing the amount of total PERK, it appears that
ERp29 facilitates cell's response to genotoxic stress that ultimately
results in the resistance against chemotherapy by DOX. This notion is
also supported by the observation that while eIF2α phosphorylation, an
immediate target of PERK activation, is not signiﬁcantly stimulated by
plasmid-mediated expression of ERp29 but amutant formof this protein
inhibited the phosphorylation of eIF2α. The latter is not consistent with
an instructive but rather with a permissive role for ERp29 in the
regulation of PERK activity.
The induction of ERp29 by DOX indicates that the above mentioned
mechanism is physiologically relevant and is consistent with the
operation of a cytoprotective cellular response that is triggered by
chemotherapy and is modulated by ERp29. Interestingly, a recent study
has shown that PERK regulates the p53/47 isoform of p53 leading to G2
arrest [26]. This ﬁnding in combination with our results implies thepresence of a regulatory loop between PERK and p53 that apparently
optimizes the cell survival: prosurvival effects triggered by DOX and
mediated by ERp29 are compensated by the speciﬁc induction of p53/
47-that causes G2 arrest.
The fact that ERp29-driven increase of PERK levels is not translated
into the activation of UPR, rules out the possibility that ERp29 may
directly regulate UPR via PERK. We have however noted that in the
clonogenic assay the phosphorylation mutant form of PERK increased
the sensitivity of A549 cells to DOX. Thus, the intact PERK activity is
associatedwith the resistance against DOX,which is consistentwith the
elevation of PERK levels following the ERp29 overexpression. BiP
overexpression has been associated with increased chemoresistance
[27] and resistance to drug-induced apoptosis through the activation of
PERK pathway [28] as well as the suppression of UPR [29,30]. Indeed,
increased binding of BiP to PERK was observed during the treatment of
cellswithDOX, however, total BiP levels remained unaffected byDOXor
by exogenous ERp29 expression. Thus, the resistance to DOX conferred
by ERp29 is not likely to be related directly to BiP in particular or to UPR
activation in general. In agreement with this notion, the modulation of
chemoresistance by BiP may be related to alternative functions of this
chaperone, other than the regulation of UPR, as proposed earlier [31].
5. Conclusions
In summary, in the present study we have identiﬁed ERp29 as a
speciﬁc regulator of PERKduringDOXtreatmentand showed that ERp29
expression is causally linked to resistance against DOX by a mechanism
that requires PERK. These ﬁndings, not only expand our limited
knowledge regarding ERp29, but also provide a direct link between
the cellular response against genotoxic stress and the execution of UPR,
identifying PERK as a nodal point between ER and genotoxic stress
induction. The evaluation of ERp29 activity may be of importance for
predicting the efﬁcacy of the chemotherapeutic response while its
speciﬁc modulation may increase the efﬁciency of anticancer therapy.
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